Scailyte AG

Scailyte pioneers single-cell biomarker discovery as this technology enters clinical trials. Our proprietary computational platform creates high-value IP and clinical assets in autoimmunity and oncology, with a model targeting Tempus AI's 10x+ ROI on data.

Our model is validated by a successful asset divestment and a pilot with a top-10 pharma now progressing to a multi-year strategic partnership. Our new IBD program leverages a cohort built on CHF 12M in public funds, plus a CHF 1M grant for our work, with LOIs currently in negotiation with two top pharma companies.

We are positioning for a Series B to scale our pharma business, targeting CHF 100M in TCV by 2027, and project a 5x-10x ROI via strategic acquisition.